Keros Therapeutics KROS 深 滬
已收盤 11-14 16:00:00 美东时间
17.26
-0.040
-0.23%
華盛通- 最 高17.63
- 今 開17.24
- 成交量 98.98万股
- 最 低 17.12
- 昨 收 17.30
- 總市值 5.26亿
- 52周最高 72.37
- 市盈率 靜 --
- 換手率 3.25%
- 52周最低 9.12
- 委 比 73.20%
- 總股本 3046.61万
- 歷史最高 88.80
- 量 比 0.71
- 振 幅 2.95%
- 歷史最低 9.12
- 每 手 1
- 風險率 12.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16
Wedbush analyst Yun Zhong maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $15 to $16.
11-06 21:35
Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(1.05) by 82.81 percent. This is a 87.23 percent increase over losses of $(1.41) per share
11-06 06:04
Keros宣布启动要约回购最多1.944亿美元股票计划
美股周一早盘，临床阶段药物开发商Keros Therapeutics（KROS）上涨2.1%，此前该公司宣布启动要约回购最多1.944亿美元自身股票。此举是...
10-20 21:55
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares
Keros Therapeutics (NASDAQ:KROS) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the tender ...
10-20 18:26
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
Keros Therapeutics has launched a $194.4 million stock buyback program under its $375 million capital return plan, offering $17.75 per share. The tender offer, set to expire on November 18, 2025, is funded from existing cash reserves. Stockholders are advised to review the offer documents and consult their advisors before deciding to tender shares. This press release is for informational purposes only, and the actual offer will be detailed in SEC...
10-20 10:00
Keros Therapeutics Announces $375M Capital Return Program
The latest announcement is out from Keros Therapeutics ( ($KROS) ). On October ...
10-15 18:57
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Boston-based biopharmaceutical company Keros Therapeutics presented data from its Phase 1 trial of KER-065, a modified activin receptor ligand trap, at the American Society of Bone and Mineral Research Annual Meeting. The trial demonstrated KER-065's safety, tolerability, and potential to improve bone mineral density in healthy male volunteers. KER-065 inhibits myostatin and activin A signaling, targeting conditions like Duchenne muscular dystrop...
09-08 12:00
